Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying vaccine therapy and sargramostim to see how well
they work compared to vaccine therapy alone in treating patients who have undergone surgery
for stage IIB, stage IIC, stage III, or stage IV melanoma. Vaccines made from peptides may
make the body build an immune response to kill tumor cells. Colony-stimulating factors such
as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
Combining vaccine therapy with sargramostim may make a stronger immune response.